Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T04388
|
||||
| Former ID |
TTDI03309
|
||||
| Target Name |
KCa2.3
|
||||
| Gene Name |
KCNN3
|
||||
| Synonyms |
KCNN3
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Myeloneuropathy [ICD10: G04.1] | ||||
| UniProt ID | |||||
| Sequence |
MDTSGHFHDSGVGDLDEDPKCPCPSSGDEQQQQQQQQQQQQPPPPAPPAAPQQPLGPSLQ
PQPPQLQQQQQQQQQQQQQQQQQQQPPHPLSQLAQLQSQPVHPGLLHSSPTAFRAPPSSN STAILHPSSRQGSQLNLNDHLLGHSPSSTATSGPGGGSRHRQASPLVHRRDSNPFTEIAM SSCKYSGGVMKPLSRLSASRRNLIEAETEGQPLQLFSPSNPPEIVISSREDNHAHQTLLH HPNATHNHQHAGTTASSTTFPKANKRKNQNIGYKLGHRRALFEKRKRLSDYALIFGMFGI VVMVIETELSWGLYSKDSMFSLALKCLISLSTIILLGLIIAYHTREVQLFVIDNGADDWR IAMTYERILYISLEMLVCAIHPIPGEYKFFWTARLAFSYTPSRAEADVDIILSIPMFLRL YLIARVMLLHSKLFTDASSRSIGALNKINFNTRFVMKTLMTICPGTVLLVFSISLWIIAA WTVRVCERYHDQQDVTSNFLGAMWLISITFLSIGYGDMVPHTYCGKGVCLLTGIMGAGCT ALVVAVVARKLELTKAEKHVHNFMMDTQLTKRIKNAAANVLRETWLIYKHTKLLKKIDHA KVRKHQRKFLQAIHQLRSVKMEQRKLSDQANTLVDLSKMQNVMYDLITELNDRSEDLEKQ IGSLESKLEHLTASFNSLPLLIADTLRQQQQQLLSAIIEARGVSVAVGTTHTPISDSPIG VSSTSFPTPYTSSSSC |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | dequalinium | Drug Info | Clinical trial | Myeloneuropathy | [1] |
| Blocker (channel blocker) | apamin | Drug Info | [2] | ||
| dequalinium | Drug Info | [1] | |||
| tetraethylammonium | Drug Info | [3] | |||
| UCL1684 | Drug Info | [2] | |||
| UCL1848 | Drug Info | [2] | |||
| Activator | CyPPA | Drug Info | [4] | ||
| DC-EBIO | Drug Info | [5] | |||
| EBIO | Drug Info | [3] | |||
| References | |||||
| REF 1 | Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83. | ||||
| REF 2 | SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34. | ||||
| REF 3 | Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. | ||||
| REF 4 | Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65. Epub 2007 May 8. | ||||
| REF 5 | Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.